Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENSBiotechnology
-$0.02 today
- Market cap
- $141.41M
- Beta
- 2.08
- P/E (TTM)
- -25.1
- EPS (TTM)
- -$0.06
Volume 0.07M
Average 0.10M
MENS Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS
Accumulated OCI · Q4 FY2025 · quarter ended Dec 2025
Accumulated OCI falls 39.2% from a year ago
Accumulated OCI stood at $682K at the end of Q4 FY2025, down 39.2% from a year earlier. Over 3 fiscal years it compounded at +4.9% a year.
Context
- Accumulated OCI amounted to 3.3% of total assets at the end of Q4 FY2025, down 14.3 pp from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -39.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 682K USD
- Year-over-year change
- -39.2%
- 4-year CAGR
- +26.5%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 682K | -39.2% |
| FY2024 | 2024-12-31 | 1.12M | +104.6% |
| FY2023 | 2023-12-31 | 548K | -7.1% |
| FY2022 | 2022-12-31 | 590K | +121.8% |
| FY2021 | 2021-12-31 | 266K | — |
Accumulated OCI vs competitors
How MENS compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -39.2% is the 5th highest of 9, against a peer median of -63.1%.
- Accumulated OCI amounts to 3.3% of total assets for MENS, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.33B CNY | +360.1% | — | 33.5% |
| Sep 2026 | $122.6M USD | +5.8% | +102.7% | 7.3% | |
| Mar 2026 | $10M USD | +3032.6% | — | 0.8% | |
| Mar 2026 | $1.41M USD | -32.1% | — | 0.2% | |
| Dec 2025 | $682K USD | -39.2% | +4.9% | 3.3% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | -$353K USD | -240.1% | — | 0.0% | |
| Sep 2026 | -$2.05M USD | -94.1% | — | 0.2% | |
| Jun 2026 | -$2.5M USD | -465.4% | -20.4% | 0.2% | |
| Sep 2026 | -$5.05M USD | -1159.3% | — | 0.4% | |
| Peer median (excluding MENS) | — | -63.1% | +41.1% | 0.2% | |
Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 551K | 718K | 177K | 98K | 1.18M |
| Short-term Investments | 1.83M | 94K | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 13.51M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 263K | 1.65M | 1.66M | 108K | 854K |
| Total Current Assets | 2.65M | 2.46M | 1.84M | 206K | 15.54M |
| Property, Plant & Equipment (Net) | 6.78M | 6M | 3.54M | 3.19M | 5.23M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 8K | 283K | 2.87M | 2.97M | 6K |
| Total Non-current Assets | 6.78M | 6.28M | 6.41M | 6.16M | 5.24M |
| Total Assets | 9.43M | 8.75M | 8.25M | 6.37M | 20.78M |
| Account Payables | 46K | 4K | 2K | 3K | 2K |
| Short-term Debt | 4.93M | 7.65M | 7.97M | 7.28M | 8.36M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 23K | 4.22M | 4.99M | 3.33M | 26.31M |
| Total Current Liabilities | 6.29M | 12.91M | 14.26M | 12.13M | 34.81M |
| Long-term Debt | 6.26M | 6.32M | 8.52M | 10.68M | 10.16M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 19.86M | 19.04M | 19.47M | 20.06M | 688K |
| Total Non-current Liabilities | 26.46M | 25.47M | 28.06M | 30.76M | 10.87M |
| Total Liabilities | 32.76M | 38.38M | 42.32M | 42.89M | 45.68M |
| Common Stock | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | (19.03M) | (25.66M) | (30.06M) | (33.08M) | (37.75M) |
| Accumulated OCI | 266K | 590K | 548K | 1.12M | 682K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (23.33M) | (29.63M) | (34.07M) | (36.52M) | (24.91M) |
| Total Debt | 11.79M | 14.25M | 16.69M | 18.14M | 18.55M |
| Net Debt | 11.24M | 13.53M | 16.51M | 18.04M | 17.37M |
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
Intrinsic Alpha fair value
Locked
Current Price
$1.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.